Nuevolution to present at Anglo-Nordic Medicinal Chemistry Symposium

Stockholm, 12 June 2017 . Nuevolution AB (publ) (NUE.ST) today announced that Thomas Franch, Chief Scientific Officer, will be presenting at the first Anglo-Nordic Medicinal Chemistry Symposium being held 11-14 June in Snekkersten, Denmark.

Dr. Franch will be presenting previously disclosed data from Nuevolution’s RORgt inhibitor program (inflammation) and bromodomain BET-BD1 selective inhibitor program (inflammation). Furthermore, the Chemetic® Platform will be described including further details from Nuevolution’s recent technology proof-of-concept study using likely the world’s largest drug discovery screening library of 40 trillion compounds.

The power of Nuevolution’s technology and in particular of this library will be illustrated with data from Nuevolution’s screening of the HIV protease. Nuevolution will present data for compounds identified directly from this library with very good properties and potencies on par or better than current marketed drugs. Based on these data, Nuevolution will evaluate the potential need for new HIV medicines before considering further HIV drug discovery.  

This library is now included for use in Nuevolution’s drug discovery projects with the anticipation that it will further increase the probability of success for tough disease targets.

For more information, please contact:

Thomas Franch, CSO

Phone: +45 7020 0987

Email: tf@nuevolution.com

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

About Chemetics™

The Nuevolution Chemetics™ platform technology comprises proprietary methods enabling DNA-encoding of compound libraries for fast and cost efficient screening of disease targets. Nuevolution annually produces up to eight Chemetics™ libraries. For further details see Nuevolution homepage: www.nuevolution.com .

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Monday 12 June 2017, 12:00 CET.

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found at: www.nuevolution.com .

Tags:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas

Subscribe

Documents & Links